



**For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment**

\* **Study Design:** Efficacy was evaluated in a 6-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. Patients had previously received one or more prior chronic ITP therapies and had average screening and baseline platelet counts of  $<30 \times 10^9/L$ . Forty-nine patients were randomized (2:1) to receive either DOPELET (n=32) or placebo (n=17).

† The primary efficacy endpoint was the cumulative number of weeks of platelet response, defined as a platelet count  $\geq 50 \times 10^9/L$  in the absence of rescue therapy, over 6 months of once-daily treatment in adults with chronic ITP.

‡ A secondary efficacy endpoint was the proportion of patients with a platelet response (platelet count  $\geq 50 \times 10^9/L$ ) at Day 8.

§ The safety of DOPELET in adults with chronic ITP was evaluated in two Phase 3 trials (one randomized, double-blind, placebo-controlled trial, and one randomized, double-blind, active-controlled trial) and two Phase 2 trials (one randomized, double-blind, placebo-controlled, dose-ranging trial, and one open-label extension trial) in 161 patients with chronic ITP. The pooled safety data from these four clinical trials includes 128 patients treated with DOPELET.

## EFFICACY

- Patients on DOPELET® (avatrombopag) were able to increase their platelet count to  $\geq 50 \times 10^9/L$  for a median of **12.4 weeks** without the need for rescue therapy ( $P < .0001$  vs placebo)<sup>†</sup>
- **66%** of patients treated with DOPELET achieved platelet counts of  $\geq 50 \times 10^9/L$  on **Day 8** ( $P < .0001$  vs placebo)<sup>‡</sup>

## ABOUT DOPELET

- **One dosage strength** helps make titration manageable for you and your patients
- DOPELET is the **only** oral TPO-RA without food-type restrictions
  - **No calcium or other food restrictions**
- DOPELET **does not require** additional liver-function monitoring
  - No significant hepatotoxicity seen in clinical trials with DOPELET
- **No office visit** for DOPELET administration required
  - Platelet count monitoring is required (see Prescribing Information for details)

## SAFETY

- Safety and tolerability profile of DOPELET was demonstrated in multiple clinical trials<sup>§</sup>

## INDICATION

DOPELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

## IMPORTANT SAFETY INFORMATION FOR DOPELET

### Warnings and Precautions

DOPELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

In clinical trials, 7% (9/128) of patients with chronic immune thrombocytopenia treated with DOPELET developed a thromboembolic event. Consider the potential increased thrombotic risk when administering DOPELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPELET should not be administered to patients with chronic immune thrombocytopenia in an attempt to normalize platelet counts. Follow the dosing guidelines to achieve target platelet counts.

**Contraindications:** None

### Drug Interactions

Dose adjustments are recommended for patients with chronic immune thrombocytopenia taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.

### Adverse Reactions

The most common adverse reactions ( $\geq 10\%$ ) were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.

**Please see Full Prescribing Information in the pocket.**

*Please contact me with any questions.*

# A RANGE OF HEALTHCARE NAVIGATION SUPPORT AND FINANCIAL ASSISTANCE TO HELP YOUR PATIENTS



Dova 1Source is the single point of contact to help your patients gain access to DOPTelet® (avatrombopag). With dedicated Care Coordinators and financial support programs, Dova 1Source provides patients with the resources they need.

After the Patient Enrollment form is completed, Dova 1Source can provide support to your eligible patients.



## Healthcare Coverage

### Dedicated Care Coordinators help:

- Patients identify personal coverage for DOPTelet
- Identify alternate coverage options if available
- Connect with appropriate Financial Assistance



## Specialty Pharmacy Coordination

- Identifies and coordinates with Specialty Pharmacy based on DOPTelet distribution network
- Supports communication between Healthcare Provider, Patient, and Specialty Pharmacy as needed



## Financial Assistance\*

- DOPTelet Copay Coupon for commercially insured patients:
  - Eligible patients pay \$0 for each DOPTelet prescription
  - The maximum benefit for each prescription is \$5,000
  - The yearly maximum benefit is \$15,000
  - State and Federally insured patients are not eligible
- Patient assistance for **uninsured/underinsured** patients
- Alternative Coverage Resources

Visit [Dova1Source.com](http://Dova1Source.com) to learn more about the Copay Coupon program

## Helping patients navigate access to DOPTelet

**To get patients started, complete the Patient Enrollment form (available at [Dova1Source.com](http://Dova1Source.com)) and fax to 1-855-686-8729**

**To speak to a Care Coordinator, please call 1-833-DOVA-ONE (1-833-368-2663)**

\*Only for eligible patients who agree to the rules set forth in the terms and conditions for the program. Please visit [Dova1Source.com](http://Dova1Source.com) for the full list of terms and conditions.

## SELECTED IMPORTANT SAFETY INFORMATION

### Warnings and Precautions

DOPTelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

In clinical trials, 7% (9/128) of patients with chronic immune thrombocytopenia treated with DOPTelet developed a thromboembolic event. Consider the potential increased thrombotic risk when administering DOPTelet to patients with known risk factors for thromboembolism,

including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTelet should not be administered to patients with chronic immune thrombocytopenia in an attempt to normalize platelet counts. Follow the dosing guidelines to achieve target platelet counts.

**Please see full Important Safety Information on front page and Full Prescribing Information in the pocket.**

**Visit [DopteletHCP.com](http://DopteletHCP.com) to learn more**

Reference: 1. DOPTelet [package insert]. Durham, NC: Dova Pharmaceuticals, Inc; 2019.

Visit [Dova.com](http://Dova.com) for WAC pricing

DOPTelet is a registered trademark of AkaRx, Inc.  
©2019 Dova Pharmaceuticals, Inc. All rights reserved. PM-US-DOP-0216v2  
Printed in USA.

**Doptelet**  
(avatrombopag) tablets